Navigation Links
XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
Date:8/6/2008

XTELL has launched a commercial biorepository service, bioVAULT, which stores, manages and processes large numbers of biological specimens. BioVAULT is targeting scientific and pharmaceutical companies investigating new drug and diagnostic development.

Athens, OH (PRWEB) August 5, 2008 -- XTELL announced today the launch of its commercialized, independent biorepository service stemming from its collaborations with The Ohio University Endocrine Diseases Biorepository. XTELL's "bioVAULT" service will provide storage of biological samples derived from human/animal serum and tissues with 100% guaranteed confidentiality. BioVAULT will allow clinicians and researchers alike to facilitate and link patient/family medical history.

XTELL is a biotechnology company founded in 2001, dedicated to both the development of biological specimen storage and electronic medical record software.

A large part of XTELL's success has been from a direct partnership with Ohio University's Diabetes Center in creating a biorepository designed specifically for fundamental and translational research. Samples include DNA, RNA, and protein extracted from blood serum in patients living in a region of the United States with a high prevalence of diabetes and endocrine-related disease. XTELL has developed one of the most advanced diabetes biorepositories of its kind, with a state-of-the-art collection and storage facility.

BioVAULT is now capable of storing, managing and processing large numbers of biological specimens. BioVAULT is targeting scientific and pharmaceutical companies investigating new drug and diagnostic development, as well as universities. "Biorepositories are now critical in understanding the molecular mechanisms of disease and for the development of new therapeutics, " said Anthony Schwartz, President of XTELL.


XTELL is privately held and located in Athens, Ohio and is seeking new investors for building up its infrastructure as well as to secure its long-term growth.

Additional information is available at: http://www.xtell.com

Contact:
XTELL
Anthony Schwartz
President
Telephone: 1.800.314.0735
E-mail: info @ xtellnetworks.com

###

Read the full story at http://www.prweb.com/releases/2008/08/prweb1174534.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community
2. Ingenuity Systems Launches Analysis Services
3. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
4. iNutrition Launches New Fission Fruit Nutrition Bars
5. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
6. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
7. Ranbaxy Launches Omeprazole 40 mg Capsules
8. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
9. GeneNews launches worlds first blood test for colorectal cancer screening
10. Norgen Biotek Corp. Launches Four New Kits for the Purification of RNA and DNA from Plants and Fungi
11. Health Market Science Launches Clinical Investigators(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies 
(Date:1/19/2017)... Md. and GAITHERSBURG, Md. ... (NYSE MKT: PIP) and Altimmune, Inc., a privately-held ... signing of a definitive agreement for the merger ... Altimmune,s current investors include Novartis Venture Fund, HealthCap, ... will be a fully-integrated and diversified immunotherapeutics company ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... and scientists from around the world, was today awarded the "Best Science & ... based entirely on merit and decided upon by a dedicated team of researchers ...
(Date:1/19/2017)... Md. , Jan. 18, 2017  Northwest Biotherapeutics, ... developing DCVax® personalized immune therapies for operable and inoperable ... Bosch , Chief Technical Officer of NW Bio, will ... January 19, 2017, at the Hyatt Regency Hotel in ... Bosch will chair the session entitled "New Therapeutic Approaches ...
(Date:1/18/2017)... -- According to a new market research report "In situ Hybridization ... End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast to ... by 2021 from USD 557.1 Million in 2016, growing at a CAGR of ... ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:1/19/2017)... , Jan. 19, 2017 ... user experience and security for consumer electronics, and ... payment processing systems and cybersecurity solutions, today announced ... enterprises and financial institutions worldwide to bolster security ... the end-to-end secure user authentication platforms they offer, ...
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/11/2017)... Johnson, co-founder of Visikol Inc. a company originally funded with an ... the elite "Forbes 30 Under 30" list in the Science category. ... fields nationwide to be recognized as a leader in business and ... ... PhD candidate at Rutgers University. Visikol , ...
Breaking Biology News(10 mins):